Zohar Daphne - 10 Nov 2026 Form 4 Insider Report for Seaport Therapeutics, Inc. (SPTX)

Reporting relationship
Chief Executive Officer, Director
Issuer ticker
SPTX
Reported as of
10 Nov 2026
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
13 Nov 2026, 08:17:49 UTC
Prior SEC filing
30 Apr 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Lana Gladstein, Attorney-in-Fact
Filing notes and source

Key filing fact

Zohar Daphne filed Form 4 for Seaport Therapeutics, Inc. (SPTX) on 13 Nov 2026.

Key facts

  • This page summarizes Zohar Daphne's Form 4 filing for Seaport Therapeutics, Inc. (SPTX).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 13 Nov 2026, 08:17.

Change

  • Previous filing in this sequence was filed on 30 Apr 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001727388 Primary reporting owner

Zohar Daphne

Relationship
Chief Executive Officer, Director
Address
SEAPORT THERAPEUTICS, INC., 101 SEAPORT BLVD., FLOOR 12, BOSTON
Signature
/s/ Lana Gladstein, Attorney-in-Fact
Signature date
13 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SPTX transaction

Common Stock

Gift

Transaction value
Shares
-100,000
Change %
-8.4%
Price
$0.000000*
Shares after
1,094,001
Date
10 Nov 2026
Ownership
Direct
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

On November 10, 2026, the Reporting Person transferred 100,000 shares of Common Stock to a donor-advised fund for no consideration.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .